Neuvivo Announces Filing of Type C Meeting Request with FDA Regarding Its Plans for Development and Marketing of NP001 for the Treatment of ALS

PALO ALTO, Calif.: PALO ALTO, Calif., Dec. 16, 2021 /PRNewswire/ -- Neuvivo, Inc., a company developing clinical-stage treatments for ALS and other neurodegenerative diseases, announced that it has submitted to the FDA a request for a Type C meeting to solicit feedback on the proposed development pathway for its lead...

Click to view original post